Stem cell

Dr. Ernst Von Schwarz: Study Shows Promising Benefit of Mesenchymal Stem Cell Injection in Critically Ill COVID-19 Patients

Monday, September 27, 2021 - 11:45pm

Neither the investigators nor the patients knew whether they received a placebo saline injection or a stem cell derived molecule product.

Key Points: 
  • Neither the investigators nor the patients knew whether they received a placebo saline injection or a stem cell derived molecule product.
  • "We don't presently have a direct treatment for COVID - 19, and patients who require hospitalization are critically ill," says Dr. von Schwarz.
  • The hypothesis is that the reduced mortality in this small study is due to anti-inflammatory effects of the stem cell injection."
  • "As a result of this study, stem cells for compassionate use are shown to be a safe and promising therapeutic approach for the treatment of critically ill patients with COVID-19.

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy

Friday, September 24, 2021 - 9:05pm

We believe Jasper is uniquely positioned with both JSP191 and its mRNA engineered stem cell platform, which have great potential individually and in combination.

Key Points: 
  • We believe Jasper is uniquely positioned with both JSP191 and its mRNA engineered stem cell platform, which have great potential individually and in combination.
  • Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell.
  • In parallel, Jasper Therapeutics is advancing its preclinical mRNA engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.
  • AMHC and Jasper Therapeutics anticipate that subsequent events and developments will cause AMHCs and Jasper Therapeutics assessments to change.

BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program

Thursday, September 23, 2021 - 2:00pm

MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowanceforapatent applicationfor its metabolic ThermoStem program.

Key Points: 
  • MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowanceforapatent applicationfor its metabolic ThermoStem program.
  • Once issued in Israel, the patent will provide patentprotection for implantable scaffolds combinedwith human brown adipose tissue stem cells, whichcan be implanted into patients.
  • We are pleased to have received this allowance since issued claims in this application provideevenbroaderprotectionthan isfound inour issued US patents, said Lance Alstodt, CEO of BioRestorative Therapies.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.

Wednesday, September 22, 2021 - 11:38pm

REDWOOD CITY, Calif. and NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC) (“AMHC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Jasper Therapeutics, Inc. (“Jasper”), a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell, and all other proposals presented at AMHC’’s special shareholder’s meeting held on September 22, 2021.

Key Points: 
  • AMHCs shareholders approved the Business Combination proposal with 74.9% votes in favor of the approximately 9,872,643 AMHC votes cast at the meeting.
  • Holders of 9,262,099 shares of AMHC Class A common stock have elected to redeem their shares in connection with the Business Combination.
  • Subject to the satisfaction or waiver of the other customary closing conditions, the Business Combination is expected to close on or about September 24, 2021.
  • AMHC and Jasper Therapeutics anticipate that subsequent events and developments will cause AMHCs and Jasper Therapeutics assessments to change.

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members

Monday, September 20, 2021 - 7:22pm

Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations.

Key Points: 
  • Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations.
  • In connection with the proposed business combination between Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation, the registration statement on Form S-4 has been declared effective by the SEC.
  • That registration statement includes the related proxy statement and prospectus of Amplitude Healthcare Acquisition Corporation with respect to Amplitude Healthcare Acquisition Corporations special meeting of stockholders.
  • In addition, the documents filed by Amplitude Healthcare Acquisition Corporation may be obtained free of charge by directing a request to Amplitude Healthcare Acquisition Corporation, 1177 Avenue of the Americas, Fl 40, New York, New York 10036.

BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors

Monday, September 20, 2021 - 1:00pm

Mike Rice, BioLife Chairman and CEO, commented, "We are thrilled with the addition of Joydeep to our board of directors.

Key Points: 
  • Mike Rice, BioLife Chairman and CEO, commented, "We are thrilled with the addition of Joydeep to our board of directors.
  • He brings a wealth of relevant life sciences tools experience and domain expertise to our board.
  • Mr. Goswami remarked, "It's my absolute pleasure to join the board of BioLife.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

Wednesday, September 15, 2021 - 1:00pm

The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioning program.

Key Points: 
  • The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioning program.
  • We are very pleased that our collaboration with the FDA has resulted in the clearance of the MGTA-117 IND.
  • We have addressed the FDAs request for a bioassay to be incorporated into the clinical trial protocol, said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics.
  • Improving conditioning treatments is essential for broadening patient accessibility to the curative potential of stem cell transplant and gene therapies.

Human Milk Supplement Shown to Boost Immunological Activity

Tuesday, September 14, 2021 - 1:38pm

The study evaluated the impact of Human Milk BionutrientsTM (HMBsTM) treatment in human-derived PBMC's against K562 cells, a commonly used immortalized leukemia cell line.

Key Points: 
  • The study evaluated the impact of Human Milk BionutrientsTM (HMBsTM) treatment in human-derived PBMC's against K562 cells, a commonly used immortalized leukemia cell line.
  • In these experiments, human milk bionutrients were added to PMBC's in the presence of K562 and treated for 48-hours.
  • Trulacta is composed entirely of thousands of beneficial components found in human milk, all of which are essential for health and wellbeing.
  • The company's flagship product Trulactais the world's first supplement for adults entirely composed of Human Milk Bionutrients (HMB's), the rich multitude of beneficial nutrients contained in human milk.

ThermoGenesis Awarded NIH SBIR Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies

Tuesday, September 14, 2021 - 1:30pm

RANCHO CORDOVA, Calif., Sept. 14, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company was awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant to develop and test the single-use sterile cell processing disposable, that will be used by the fully automated Quintessence System. These programs allow US-owned life science companies that are creating innovative technologies that align with NIH's mission to improve health and save lives to engage in federal research and development that has a strong potential for commercialization. This technology is protected by 15 issued patents and 13 pending applications.

Key Points: 
  • Current automation efforts do not offer a solution, because the cell processing techniques they automate are themselves inefficient (in terms of cell recoveries).
  • This enhanced cell processing cartridge will be integrated into a 'one-pot' GEAC manufacturing workflow lending itself to full automation in the simple, compact, moderately priced Quintessence instrument (the subject of a follow-on Phase 2 SBIR proposal."
  • A key objective is to translate promising technologies to the private sector and enable life-saving innovations to reach consumer markets.
  • ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies.